Insulin Resistance and Reward (IRRSO)
Primary Purpose
Obesity
Status
Completed
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
Weight loss
Sponsored by
About this trial
This is an interventional other trial for Obesity focused on measuring Insulin resistance, Consummatory Reward
Eligibility Criteria
Inclusion Criteria:
- Age 25-60yoa, inclusive.
- BMI 30.0 and 45.0 kg/m2, inclusive.
- Normal visual acuity with correction.
- Able to travel regularly to the St. Louis VA and Washington University for research visits.
- Completed signed informed consent form.
Exclusion Criteria:
- Current or history of significant psychiatric disease, including Binge Eating Disorder (BED).
- Current or history of significant substance abuse or extended use of tobacco.
- Contraindications for MRI (e.g., pregnancy, claustrophobia, pacemaker, circumference > 54 inches, weight > 400 lbs, etc.);
- Significant cardiovascular, pulmonary, renal, liver, neurologic, or metabolic disease.
- Diabetes mellitus.
- Significant anemia.
- Treatment with a medication the affects insulin sensitivity.
- Treatment with centrally acting medications.
- Frequent shift work.
- Significant in-mobility or unable to lay on back still for 1 hour.
- History of bariatric surgery.
- Food allergies/ intolerance that would prevent completing study.
- Symptoms concerning for untreated active mental health disease
Sites / Locations
- St. Louis VA Medical Center John Cochran Division, St. Louis, MO
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
No Intervention
Arm Label
Weight loss
Baseline comparator
Arm Description
Obese Veterans will aim to lose 5-10% body weight
Obese Veterans similar to Aim 1 in BMI, age, gender but not insulin sensitivity will not undergo weight loss
Outcomes
Primary Outcome Measures
food consumption-induced neural activation
food consumption-induced neural activation as determined by blood-oxygen dependent functional magnetic resonance imaging (BOLD fMRI) scanning
Secondary Outcome Measures
Full Information
NCT ID
NCT02241603
First Posted
September 11, 2014
Last Updated
July 7, 2020
Sponsor
VA Office of Research and Development
Collaborators
Washington University School of Medicine
1. Study Identification
Unique Protocol Identification Number
NCT02241603
Brief Title
Insulin Resistance and Reward
Acronym
IRRSO
Official Title
Insulin Resistance and Reward Signaling in Obesity
Study Type
Interventional
2. Study Status
Record Verification Date
July 2020
Overall Recruitment Status
Completed
Study Start Date
November 17, 2014 (Actual)
Primary Completion Date
July 1, 2020 (Actual)
Study Completion Date
July 1, 2020 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
VA Office of Research and Development
Collaborators
Washington University School of Medicine
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
Obesity is a common problem in the Veteran population as at least 1 in 3 Veterans are obese. When obese people eat food they have less response in areas of the brain that sense pleasure (reward). Decreased pleasure response to food predicts future weight gain. It is not known if this poor brain response is reversible or why obese people's brains respond this way. Insulin in the brain regulates the brain's sensing of pleasure. As people gain weight the function of insulin becomes impaired. The investigators will study if impaired function of insulin is related to a poor brain response to food and if this brain response predicts voluntary intake of food and response to a diet. The investigators will also study if improving the function of insulin with weight loss improves the brain response. These studies will improve the understanding as to why weight loss is difficult and inform us if improving insulin signaling is a potential way to treat obesity.
Detailed Description
The current research proposal will investigate the relationship of insulin sensitivity to brain reward signaling. In most obese individuals, insulin signaling is impaired (insulin resistance). Preclinical animal studies suggest that insulin resistance in brain regions important for reward contribute to overeating. This proposal aims to test these hypotheses in humans and to determine if these characteristics are pertinent to clinical outcomes (food intake and weight loss). In humans increased body mass index (BMI) and weight gain occur with decreased food consumption-induced neural activation (consummatory reward) in the caudate of the dorsal striatum. It has been speculated that diminished consummatory reward causes overeating and prevents weight loss, however, this hypothesis has not been directly tested. Further, mechanisms for impaired food consumption-induced neural activation in obesity have not been investigated.
The primary research outcomes of the proposed study are: 1) insulin sensitivity determined by hyperinsulinemic euglycemic clamp, 2) food consumption-induced neural activation as determined by blood-oxygen dependent functional magnetic resonance imaging (BOLD fMRI) scanning, 3) caloric intake at a buffet meal, and 4) weight loss during a weight loss intervention. Based on screening and baseline outcome assessments half of participants will be enrolled in a weight loss intervention and then repeat outcomes measures after intervention. Others will only complete baseline outcome measures. Secondary measures of the study include whole brain activation analyses, neuroendocrine hormone measurement at the time of imaging, psychometric measures including eating behaviors and personality characteristics, and measures of reward sensitivity.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Obesity
Keywords
Insulin resistance, Consummatory Reward
7. Study Design
Primary Purpose
Other
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Model Description
Participants are assigned to two groups in parallel for the duration of the study. There is a dietary weight loss intervention aiming for ~5-10% weight loss
Masking
Participant
Masking Description
participants are expressly assigned to intervention groups through a non-random method based on metabolic testing
Allocation
Non-Randomized
Enrollment
59 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Weight loss
Arm Type
Experimental
Arm Description
Obese Veterans will aim to lose 5-10% body weight
Arm Title
Baseline comparator
Arm Type
No Intervention
Arm Description
Obese Veterans similar to Aim 1 in BMI, age, gender but not insulin sensitivity will not undergo weight loss
Intervention Type
Behavioral
Intervention Name(s)
Weight loss
Intervention Description
Obese Veterans will undergo dietary education for weight loss or weight maintenance
Primary Outcome Measure Information:
Title
food consumption-induced neural activation
Description
food consumption-induced neural activation as determined by blood-oxygen dependent functional magnetic resonance imaging (BOLD fMRI) scanning
Time Frame
~4-9months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
25 Years
Maximum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Age 25-60yoa, inclusive.
BMI 30.0 and 45.0 kg/m2, inclusive.
Normal visual acuity with correction.
Able to travel regularly to the St. Louis VA and Washington University for research visits.
Completed signed informed consent form.
Exclusion Criteria:
Current or history of significant psychiatric disease, including Binge Eating Disorder (BED).
Current or history of significant substance abuse or extended use of tobacco.
Contraindications for MRI (e.g., pregnancy, claustrophobia, pacemaker, circumference > 54 inches, weight > 400 lbs, etc.);
Significant cardiovascular, pulmonary, renal, liver, neurologic, or metabolic disease.
Diabetes mellitus.
Significant anemia.
Treatment with a medication the affects insulin sensitivity.
Treatment with centrally acting medications.
Frequent shift work.
Significant in-mobility or unable to lay on back still for 1 hour.
History of bariatric surgery.
Food allergies/ intolerance that would prevent completing study.
Symptoms concerning for untreated active mental health disease
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Julia P Dunn, MD
Organizational Affiliation
St. Louis VA Medical Center John Cochran Division, St. Louis, MO
Official's Role
Principal Investigator
Facility Information:
Facility Name
St. Louis VA Medical Center John Cochran Division, St. Louis, MO
City
Saint Louis
State/Province
Missouri
ZIP/Postal Code
63106
Country
United States
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Insulin Resistance and Reward
We'll reach out to this number within 24 hrs